Agios Pharmaceuticals presents data from Phase 1 Study of AG-270.
Agios Pharmaceuticals presented the first data from the single agent dose-escalation arm of the Phase 1 study of AG-270 in methylthioadenosine phosphorylase-deleted tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. AG-270 is an investigational, first-in-class methionine adenosyltransferase 2A inhibitor. "The single agent arm of the Phase 1 trial for AG-270 provides the first data from a clinical study of a MAT2A inhibitor," said Rebecca Heist, M.D., Massachusetts General Hospital and an investigator in the study. "These data demonstrate that AG-270 induces reductions in the biomarkers of MAT2A inhibition, notably plasma concentrations of S-adenosylmethionine and tumor levels of symmetrically demethylated arginine, at well tolerated doses. These findings will help guide the dosing and schedule for the next phase of development of AG-270 in combination with taxanes."
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 27, 2019|
|Previous Article:||Merus says MCLA-128 shows 'encouraging' early clinical activity.|
|Next Article:||PG&E to cut power to approximately 940K customers due to weather.|